Larissa C.Bergin

Larissa Bergin's practice addresses emerging issues arising out of regulator enforcement of, and commentary on, the antitrust laws. Whether client antitrust concerns arise from M&A matters, joint ventures, federal and state investigations, or commercial practices, Larissa focuses on taking a proactive approach to mitigate antitrust risks in the current antitrust climate.

Larissa represents clients in a variety of industries, including the technology, financial services, health care, pharmaceutical, and retail sectors. By means of example, Larissa advises financial institutions and other companies regarding ESG-related (environmental, social, and governance) risks and represents them during investigations. She also is heavily involved in pharmaceutical and health care-related transactions and investigations arising from regulator concerns over innovation, pricing, and entry.

Larissa has overseen the antitrust aspects of corporate M&A, including due diligence, risk-shift negotiations, Hart-Scott-Rodino (HSR) filings, Second Requests, investigational hearings, integration planning, and consent decrees with federal agencies. Many of Larissa's clients have an international reach, and she has been involved in matters that require advocacy before governments throughout Asia, the European Union, and North America.

Larissa is chair of the Food, Drug and Cosmetics Law Section of the New York State Bar Association. She also has been quoted on MSNBC regarding how Obamacare has affected M&A activity and in Getting the Deal Through on generic drug approval.

She is admitted in New York, Connecticut, and the District of Columbia.